bit.bio + Pint of Science

SubscribeSpotify | TuneIn | Stitcher | Apple

We have a special three part mini-series of podcasts in collaboration with bit.bio, the cell-coding company. Find out how bit.bio is developing a scalable technology platform capable of producing consistent batches of every human cell. By harnessing the power of mathematics and transitioning biology to engineering, bit.bio aims to accelerate biomedical research and enable new generations of cures. 

Sam hosts the conversations with some of bit.bio’s inspiring leaders, discussing the pioneering work into stem cells, cellular reprogramming, mathematical modelling, and cell therapy.

You can follow bit.bio on twitter @bitbio

Episode 1: CEO and founder Dr Mark Kotter

The series kicks off with Dr Mark Kotter, founder and CEO of bit.bio, the cell coding company. He covers the concept of regenerative medicine and in particular how we might use this approach for neurological conditions and spinal cord injuries – he has a personal interest as he’s a neurosurgeon as well as a CEO and founder. He reveals how bit.bio is working to harness the power of stem cells and turn them into medicines by looking at biology in a different way – like a software.

Headshot of Dr Mark Kotter

Dr Mark Kotter

Mark said: “We were able to create a control system that allows us to jumpstart the programs of the cell very effectively. We call this opti-ox™ - it takes full control of the cells identity and has made the process of cell reprogramming very robust and therefore scalable.

You can find Mark on Twitter @MarkKotter 

Interested in precise reprogramming of cells? See the video of bit.bio’s opti-ox™ technology reprogramming stem cells into functional skeletal muscle.

Episode 2: Dr Paul Morrill (CBO - Chief Business Officer)

The series continues with Dr Paul Morrill, who discusses bit.bio’s central core - to develop the underlying technologies capable of producing consistent batches of every cell type in the human body. He explains that the drive is to get the context of the biological system right so that it can be studied within the whole context of how it should be performing, be it healthy or in a disease state.

Headshot of Paul Morrill

Dr Paul Morrill

Paul explains: “The day for iPSC cell types is coming. And the value proposition of what they’re going to bring to the industry - both as an avatar for what is happening within the human body, but then equally being able to ask very intelligent questions from those systems - is going to be game changing over the next five years.”

Interested in learning more on how bit.bio apply synthetic biology to generate consistent and scalable stem cell derived human cells for research and drug discovery? Listen to the talk, Coding Cells for Life: Consistent and scalable human iPSC-derived cells for in vitro disease modelling and drug discovery